Table 4.
Antibiotic therapy.
| SCT, n = 59 (15.1%) | LCT, n = 331 (84.9%) | p-Value | |
|---|---|---|---|
| Initial antimicrobial therapy | |||
| Ampicillin/sulbactam | 8 (13.6%) | 60 (18.1%) | 0.461 |
| Piperacillin/tazobactam | 8 (13.6%) | 47 (14.2%) | >0.99 |
| Ceftriaxone | 3 (5.1%) | 17 (5.1%) | >0.99 |
| Cefmetazole | 38 (64.4%) | 189 (57.1%) | 0.319 |
| Meropenem | 0 (0.0%) | 8 (2.4%) | 0.613 |
| Ciprofloxacin | 0 (0.0%) | 9 (2.7%) | 0.366 |
| Levofloxacin | 0 (0.0%) | 1 (0.3%) | >0.99 |
| Vancomycin | 0 (0.0%) | 1 (0.3%) | >0.99 |
| Others | 0 (0.0%) | 1 (0.3%) | >0.99 |
| No antibiotics | 2 (3.4%) | 0 (0.0%) | 0.023 |
| Median time from first physician contact to antibiotic administration (range) | 5.0 h | 4.0 h | 0.039 |
| (0–96) | (0–53) | ||
| Median total duration of antimicrobial therapy (range) | 2 days | 5 days | <0.001 |
| (0–12) | (3–49) | ||
| Only pathogens resistant to the initial antibiotics | 23 (39.0%) | 72 (21.8%) | 0.008 |
SCT: short-course antibiotic therapy; LCT: long-course antibiotic therapy.